CN102382188B - Method for preparing carperitide acetate - Google Patents
Method for preparing carperitide acetate Download PDFInfo
- Publication number
- CN102382188B CN102382188B CN201110347965.4A CN201110347965A CN102382188B CN 102382188 B CN102382188 B CN 102382188B CN 201110347965 A CN201110347965 A CN 201110347965A CN 102382188 B CN102382188 B CN 102382188B
- Authority
- CN
- China
- Prior art keywords
- carperitide
- phase
- wang resin
- fmoc
- tbu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 title claims abstract description 31
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 title claims abstract description 30
- 229950008486 carperitide Drugs 0.000 title claims abstract description 30
- 102000056614 human NPPA Human genes 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 60
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000010168 coupling process Methods 0.000 claims abstract description 17
- 230000008878 coupling Effects 0.000 claims abstract description 16
- 238000005859 coupling reaction Methods 0.000 claims abstract description 16
- 238000006467 substitution reaction Methods 0.000 claims abstract description 16
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 claims abstract description 14
- 238000004007 reversed phase HPLC Methods 0.000 claims abstract description 11
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 8
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 claims abstract description 7
- 230000001590 oxidative effect Effects 0.000 claims abstract description 5
- 238000005336 cracking Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 41
- 239000012071 phase Substances 0.000 claims description 36
- 239000011347 resin Substances 0.000 claims description 27
- 229920005989 resin Polymers 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 12
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 239000011630 iodine Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 230000005526 G1 to G0 transition Effects 0.000 claims description 8
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000007822 coupling agent Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 239000003875 Wang resin Substances 0.000 abstract description 10
- 230000002194 synthesizing effect Effects 0.000 abstract description 7
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 abstract description 6
- 230000003647 oxidation Effects 0.000 abstract description 6
- 239000007790 solid phase Substances 0.000 abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000003756 stirring Methods 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000005406 washing Methods 0.000 description 16
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000012317 TBTU Substances 0.000 description 6
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- -1 9-fluorenylmethyloxycarbonyl Chemical group 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AOMBSGWDTLEHOO-QFIPXVFZSA-N (2s)-2-(9h-fluoren-1-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C2=C(C3=CC=CC=C3C2)C=CC=1)C1=CC=CC=C1 AOMBSGWDTLEHOO-QFIPXVFZSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 101100338765 Danio rerio hamp2 gene Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Abstract
The invention discloses a method for preparing carperitide acetate. The method comprises the following steps of: 1) reacting Fmoc-Tyr(tBu)-OH with WangResin with the substitution value of 0.5-1.0mmol/g to obtain Fmoc-Tyr(tBu)-WangResin; 2) synthesizing the Fmoc-Tyr(tBu)-WangResin by adopting a mode of coupling one by one to obtain linear carperitide-WangResin; 3) oxidizing the carperitide-WangResin by using a solid-phase oxidation method; 4) cracking by using trifluoroacetic acid to obtain crude carperitide; and 5) purifying the crude carperitide by using reversed phase high performance liquid chromatography to obtain high-purity refined carperitide. The process has the advantages of simple reaction and operation, simple posttreatment, high yield, low cost and the like.
Description
Technical field
The present invention relates to the preparation method of a peptide species, relate in particular to a kind of preparation method of carperitide acetate.
Background technology
The contained Carperitide of this product, another name gene recombination atrial natriuretic peptide, card piperazine profit fourth, Hamp, human brain natriuretic peptide.Its indication is acute heart failure (comprising that chronic heart failure increases the weight of).; Carperitide pharmacotoxicological effect is by stimulating cardiac muscle to stretch, being synthesized by ventricle endoparticle, and then by coronary artery distribution whole body, the tissues such as vasoactive unstriated muscle and kidney, regulate blood pressure and cylinder electrolyte balance.This product is that a kind of circulation that 28 amino acid form regulates hormone, plays vasodilation and diuretic properties.The vasorelaxation that this product causes is due to the ANP with vascular smooth muscle (atrial natriuretic polypeptins) receptors bind, and by improving, the activity of guanylate cyclase realizes, and prompting can alleviate the forward and backward load of heart.
At present domestic have one piece of Carperitide patent (patent No.: ZL200510012425.5), employing be that gene recombination technology is produced, have no the report of process for solid phase synthesis method; CA1245635A1 patent report for adopting the synthetic Carperitide of Boc route, CA1245637A1 patent report for adopting gene recombination technology production Carperitide, other patent, as EP0440311A1, JP3004169A, US4673732A etc. are or adopt gene recombination technology production Carperitide or adopt the synthetic Carperitide of Boc route, has no the pertinent literature and the patent that adopt the synthetic Carperitide of Fmoc route.
Summary of the invention
The present invention proposes a kind of preparation method who adopts solid phase Fmoc synthesizing linear Carperitide, whole technological operation is convenient, yield is high.
A kind of method of preparing carperitide acetate provided by the invention, comprises the following steps:
1) the Wang Resin that is 0.5mmol/g-1.0mmol/g by Fmoc-Tyr (tBu)-OH and substitution degree reaction, obtains Fmoc-Tyr (tBu)-Wang Resin;
2) Fmoc-Tyr (tBu)-Wang Resin resin is adopted to the mode of coupling is one by one synthetic obtains linear Carperitide-Wang Resin;
3) adopt solid-phase oxidation method oxidation Carperitide-Wang Resin;
4) adopt TFA cracking, obtain thick peptide;
5) through Reversed phase high performance liquid chromatography purifying, freeze-drying, obtain carperitide acetate.
The present invention is with respect to Boc method, and Fmoc method is simple to operate, and environmental pollution is little.
Adopt Wang Resin(Wang-resin) not only cost is low, more has social value, and Wang Resin can make whole solid phase synthesis stable.Applicant is surprised to find that, the yield important of the substitution degree of Wang resin to reaction during this is synthetic, and when the substitution degree of wang resin is greater than 1.0mmol/g, the yield of synthetic product Carperitide obviously reduces; When the substitution degree of Wang resin is during lower than 1.0mmol/g, yield is more stable, but when substitution degree is during lower than 0.5mmol/g, Wang resin consumption can increase considerably, very large to the cost impact of sintetics Carperitide.In order to seek the best joint of yield and cost, the Wang Resin that it is 0.5mmol/g-1.0mmol/g that the present invention takes with substitution degree.
The present invention adopts the mode of coupling one by one to synthesize and obtains linear Carperitide-Wang Resin, and the coupling agent that coupling process adopts comprises DIC/HOBt, PyBOP/HOBt or TBTU/HOBt.Adopt organic bases to comprise TEA, NMM or DIPEA simultaneously.Preferred system is TBTU/HOBt system, and preferably organic bases is NMM.Experiment is found, is adopted multiple coupling system of the present invention can significantly improve reaction efficiency.Applicant is surprised to find that, organic bases is TEA, NMM or DIPEA, can effectively prevent synthetic product racemization.
Adopt solid phase iodine oxidation style being applied to be oxidized Carperitide-Wang Resin, the consumption of iodine is a very important factor, when the amount of iodine is greater than 80 times of Carperitide-Wang Resin amount, because consumption is too high, cause oxidation products complicated, be difficult to purifying; When the amount of iodine is less than 10 times of Carperitide-Wang Resin amount, the yield of oxidation is very low, causes reaction efficiency low.Applicant finds unexpectedly, when the amount of iodine is 10-80 times of Carperitide-Wang Resin amount, and an ideal range of be balance reaction efficiency and purifying difficulty.Wherein oxidization time is defined as 4-16 hour.
Described step 5) Carperitide Reversed phase high performance liquid chromatography purifying comprises the following steps:
The first step purifying: will synthesize the thick peptide dissolving of gained rear is stationary phase with octadecylsilane chemically bonded silica, take phosphate buffer soln as A phase, and buffered soln pH scope is 2.5-3.5; Trifluoroacetic acid aqueous solution is B phase, and the gradient of B phase is: 17%～32%, carry out gradient elution purifying 45-120min.Phosphate buffer soln can be the phosphate buffer solution of 0.1-0.2% for volumetric concentration;
Second step turns salt: adopt RP-HPLC method to be changed into acetate.Acetate buffer solution concentration as A phase should be 0.5--0.1%; Buffered soln pH should be 3.5～4.4; The gradient that second step turns the trifluoroacetic acid aqueous solution B phase of salt is: 6%～36%, and the gradient elution time is 30--90 min.The english abbreviation of minShi unit minute wherein.
Adopt this purification process, can make that whole production process controllability is high, favorable reproducibility, can obtain very high productive rate simultaneously.
Synthetic method exemplary flow of the present invention is as follows:
Wherein:
Fmoc-Tyr (tBu)-OH representative: N-fluorenylmethyloxycarbonyl-side chain tertiary butyl protection tyrosine
Fmoc-Arg (R)-OH representative: N-fluorenylmethyloxycarbonyl-side chain R base protection arginine
Fmoc-Phe-OH representative: N-fluorenylmethyloxycarbonyl phenylalanine
Fmoc-Ser (R)-OH representative: N-fluorenylmethyloxycarbonyl-side chain R base protection Serine
Fmoc-Asn (R)-OH representative: N-fluorenylmethyloxycarbonyl-side chain R base protection l-asparagine
Fmoc-Cys (R)-OH representative: N-fluorenylmethyloxycarbonyl-side chain R base protection halfcystine
Fmoc-Gly-OH representative: N-fluorenylmethyloxycarbonyl glycine
Fmoc-Leu-OH representative: N-fluorenylmethyloxycarbonyl leucine
Fmoc-Gln (R)-OH representative: N-fluorenylmethyloxycarbonyl-side chain R base protection glutamine
Fmoc-Ala-OH representative: N-fluorenylmethyloxycarbonyl L-Ala
Fmoc-Ile-OH representative: N-fluorenylmethyloxycarbonyl Isoleucine
Fmoc-Asp (R)-OH representative: N-fluorenylmethyloxycarbonyl-side chain R base protection aspartic acid
Fmoc-Met-OH representative: N-fluorenylmethyloxycarbonyl-methionine(Met)
When amino acid is arginine, side chain R=pbf(2,2,4,6,7-pentamethyl-benzo furans-5-alkylsulfonyl); When amino acid is Serine, aspartic acid, the side chain R=tBu(tertiary butyl); When amino acid is halfcystine, glutamine, l-asparagine, side chain R=Trt (trityl).
DIC representative: DIC
DMAP representative: 4, DMAP
HOBt representative: 1-hydroxy benzo triazole
TBTU representative: O-benzotriazole-N, N, N', N'-tetramethyl-urea Tetrafluoroboric acid ester
TFA representative: trifluoroacetic acid
TEA representative: triethylamine
Technique of the present invention has that operation is simple, aftertreatment easily, low, the yield high of raw material less investment, cost, the total recovery of total overall reaction can reach 30%.
There is considerable economical and practical value, in the synthetic field of polypeptide drugs design, be with a wide range of applications simultaneously.
Embodiment
Below in conjunction with drawings and Examples, the present invention is described in further details.
Wang Resin is purchased from Tianjin Nankai He Cheng company limited, and various protected amino acids are purchased from the biochemical company limited of gill.In specification sheets and claims, the implication of the english abbreviation that uses is listed in the following table:
| Fmoc | 9-fluorenylmethyloxycarbonyl |
| DIC | DIC |
| HOBt | I-hydroxybenzotriazole |
| DIPEA | DIPEA |
| NMM | N-methylmorpholine |
| Pbf | 2,2,4,6,7-pentamethyl-benzo furans-5-alkylsulfonyl |
| Trt | Trityl |
| tBu | The tertiary butyl |
| DMF | DMF |
| DCM | Methylene dichloride |
| DMF | Dimethyl methyl methane amide |
| TFA | Trifluoroacetic acid |
| DMAP | 4, DMAP |
| TBTU | O-benzotriazole-N, N, N', N'-tetramethyl-urea Tetrafluoroboric acid ester |
Embodiment 1, Fmoc-Tyr (tBu)-Wang Resin's is synthetic
In the reaction column of 50ml, add 4.8 grams of Wang Resin(sub=0.5mmol/g), add DMF swelling 30 minutes, and with appropriate DMF washing resin three times.Take Fmoc-Tyr (tBu)-OH (2.89g, 6.3mmol), HOBT (1.02g, 7.56mmol), after all mixing, adds DMF (10ml), DCM (10ml) stirring and dissolving complete.Then add DIC (0.98ml, 6.3mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column, and adds DMAP(29.3mg, 0.24mmol), drum nitrogen reaction 3h.Drain reaction solution, and with DMF washing resin 4 times, then add diacetyl oxide (16.2ml, 180mmol), pyridine ((13.8ml, 180mmol), reaction 2h.Drain reaction solution, and with DMF washing resin 6 times.Vacuum-drying, it is 0.3mmol/g that its substitution value is surveyed in sampling.
Embodiment 2, Fmoc-Tyr (tBu)-Wang Resin's is synthetic
In the reaction column of 50ml, add 3.0 grams of Wang Resin(sub=0.8mmol/g), add DMF swelling 30 minutes, and with appropriate DMF washing resin three times.Take Fmoc-Tyr (tBu)-OH (2.89g, 6.3mmol), HOBT (1.02g, 7.56mmol), after all mixing, adds DMF (10ml), DCM (10ml) stirring and dissolving complete.Then add DIC (0.98ml, 6.3mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column, and adds DMAP(29.3mg, 0.24mmol), drum nitrogen reaction 3h.Drain reaction solution, and with DMF washing resin 4 times, then add diacetyl oxide (16.2ml, 180mmol), pyridine ((13.8ml, 180mmol), reaction 2h.Drain reaction solution, and with DMF washing resin 6 times.Vacuum-drying, it is 0.4mmol/g that its substitution value is surveyed in sampling.
Embodiment 3, Fmoc-Tyr (tBu)-Wang Resin's is synthetic
In the reaction column of 50ml, add 2.4 grams of Wang Resin(sub=1.0mmol/g), add DMF swelling 30 minutes, and with appropriate DMF washing resin three times.Take Fmoc-Tyr (tBu)-OH (2.89g, 6.3mmol), HOBT (1.02g, 7.56mmol), after all mixing, adds DMF (10ml), DCM (10ml) stirring and dissolving complete.Then add DIC (0.98ml, 6.3mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column, and adds DMAP(29.3mg, 0.24mmol), drum nitrogen reaction 3h.Drain reaction solution, and with DMF washing resin 4 times, then add diacetyl oxide (16.2ml, 180mmol), pyridine ((13.8ml, 180mmol), reaction 2h.Drain reaction solution, and with DMF washing resin 6 times.Vacuum-drying, it is 0.6mmol/g that its substitution value is surveyed in sampling.
Embodiment 4, linear Carperitide-Wang Resin's is synthetic
By DMF swelling 30 minutes for 5mmol Fmoc-Tyr (tBu)-Wang Resin (substitution value=0.4mmol/g), drain solvent, add 20% hexahydropyridine/DMF to react 30min, drain reaction solution, and with DMF washing resin 6 times.Take Fmoc-Arg (pbf)-OH (9.732g, 15mmol), HOBT (2.027g, 15mmol), after all mixing, add DMF (30ml), DCM (30ml) stirring and dissolving complete.Then add DIC (2.355ml, 15mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column to drum nitrogen reaction 2h.Drain reaction solution, repeat protection, coupling operation, coupling synthesizing linear Carperitide-Wang Resin 47.233g progressively successively, resin synthesis yield 106.3%.
Embodiment 5, linear Carperitide-Wang Resin's is synthetic
By DMF swelling 30 minutes for 5mmol Fmoc-Tyr (tBu)-Wang Resin (substitution value=0.4mmol/g), drain solvent, add 20% hexahydropyridine/DMF to react 30min, drain reaction solution, and with DMF washing resin 6 times.Take Fmoc-Arg (pbf)-OH (9.732g, 15mmol), PyBOP (7.806g, 15mmol), HOBT (2.027g, 15mmol), after all mixing, add DMF (30ml), DCM (30ml) stirring and dissolving complete.Then add NMM (3.33ml, 30mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column to drum nitrogen reaction 2h.Drain reaction solution, repeat protection, coupling operation, coupling synthesizing linear Carperitide-Wang Resin 47.695g progressively successively, resin synthesis yield 108.1%.
Embodiment 6, linear Carperitide-Wang Resin's is synthetic
By DMF swelling 30 minutes for 5mmol Fmoc-Tyr (tBu)-Wang Resin (substitution value=0.4mmol/g), drain solvent, add 20% hexahydropyridine/DMF to react 30min, drain reaction solution, and with DMF washing resin 6 times.Take Fmoc-Arg (pbf)-OH (9.732g, 15mmol), PyBOP (7.806g, 15mmol), HOBT (2.027g, 15mmol), after all mixing, add DMF (30ml), DCM (30ml) stirring and dissolving complete.Then add DIPEA (4.965ml, 30mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column to drum nitrogen reaction 2h.Drain reaction solution, repeat protection, coupling operation, coupling synthesizing linear Carperitide-Wang Resin 47.102g progressively successively, resin synthesis yield 105.8%.
Embodiment 7, linear Carperitide-Wang Resin's is synthetic
By DMF swelling 30 minutes for 5mmol Fmoc-Tyr (tBu)-Wang Resin (substitution value=0.4mmol/g), drain solvent, add 20% hexahydropyridine/DMF to react 30min, drain reaction solution, and with DMF washing resin 6 times.Take Fmoc-Arg (pbf)-OH (9.732g, 15mmol), TBTU (4.817g, 15mmol), HOBT (2.027g, 15mmol), after all mixing, add DMF (30ml), DCM (30ml) stirring and dissolving complete.Then add NMM (3.33ml, 30mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column to drum nitrogen reaction 2h.Drain reaction solution, repeat protection, coupling operation, coupling synthesizing linear Carperitide-Wang Resin 46.936g progressively successively, resin synthesis yield 105.1%.
Embodiment 8, linear Carperitide-Wang Resin's is synthetic
By DMF swelling 30 minutes for 5mmol Fmoc-Tyr (tBu)-Wang Resin (substitution value=0.4mmol/g), drain solvent, add 20% hexahydropyridine/DMF to react 30min, drain reaction solution, and with DMF washing resin 6 times.Take Fmoc-Arg (pbf)-OH (9.732g, 15mmol), TBTU (4.817g, 15mmol), HOBT (2.027g, 15mmol), after all mixing, add DMF (30ml), DCM (30ml) stirring and dissolving complete.Then add DIPEA (4.965ml, 30mmol), under room temperature, stir 20min.Reaction solution is transferred in reaction column to drum nitrogen reaction 2h.Drain reaction solution, repeat protection, coupling operation, coupling synthesizing linear Carperitide-Wang Resin 46.835g progressively successively, resin synthesis yield 104.8%.
The phase oxidative of embodiment 9, Carperitide-Wang Resin
Take iodine (12.69g, 50mmol), add DMF (100ml), stirring and dissolving is complete.Linear Carperitide-Wang the Resin that adds any one embodiment of embodiment 4-8 to prepare the iodine/DMF solution having dissolved, drum nitrogen gas stirring reaction 6h.Drain reaction solution, DMF washing resin 6 times, methanol wash resin 3 times, vacuum-drying, obtains Carperitide-Wang Resin.
The phase oxidative of embodiment 10, Carperitide-Wang Resin
Take iodine (101.52g, 400mmol), add DMF (800ml), stirring and dissolving is complete.Linear Carperitide-Wang the Resin that adds any one embodiment of embodiment 4-8 to prepare the iodine/DMF solution having dissolved, drum nitrogen gas stirring reaction 1.5h.Drain reaction solution, DMF washing resin 6 times, methanol wash resin 3 times, vacuum-drying, obtains Carperitide-Wang Resin.
The TFA cracking of embodiment 11, Carperitide-Wang Resin
Take in embodiment 10 gained Carperitide-Wang Resin to 1L round-bottomed flasks, add 500ml lysate (TFA: methyl-phenoxide: water=90:5:5), room temperature reaction 5h.Filtration under diminished pressure, filtrate adds the freezing ether sedimentation of 5L centrifugal.The 17.203g that weighs after the thick peptide vacuum-drying of gained, thick peptide yield 111.7%.
Embodiment 12: Carperitide Reversed phase high performance liquid chromatography purifying
1. sample preparation: dissolve the inorganic membrane filtration of the solution after dissolving, collection filtrate for later use according to every gram of thick peptide 100 ml pure water ratios.
2. purifying
Condition: chromatographic column: the chromatographic column that the octadecylsilane chemically bonded silica of take is stationary phase, pillar diameter and length are:
50mm?×?300mm?。Moving phase: A phase: 0.2% phosphoric acid solution is adjusted pH to 2.5～3.5 with triethylamine; B phase: acetonitrile.Flow velocity: 70-80 ml/min.Detect wavelength: 230 nm.Gradient: B%:17%～32%(45 min).Sample size is 1.3-1.5 g.
Operation: rinse chromatographic column well back balance loading with more than 50% acetonitrile, applied sample amount is 1.3-1.5g.Linear gradient elution 45min, collects object peak, and the object peptide solution of collection is standby after 28 ℃ of vacuum rotary steams are concentrated into approximately 10～12 mg/ml.
3, turn salt:
Condition: chromatographic column: the chromatographic column that the octadecylsilane chemically bonded silica of take is stationary phase, pillar diameter and length are: 50mm * 300mm.Moving phase: A phase: the aqueous acetic acid of mass concentration 0.1%; B phase: trifluoroacetic acid aqueous solution.Flow velocity: 70-80 ml/min.Detect wavelength: 230 nm.Gradient: B%:6%～36%(30 min).Sample size is 1.6-2.0g.
Operation: rinse chromatographic column well rear loading with more than 50% acetonitrile, applied sample amount is 160-200ml sample solution.Linear gradient elution 30min, collects object peak, the object peptide solution of collection is merged to concentrated by rotary evaporation and to about 50-80mg/ml, go to suitable big or small cillin bottle.Lyophilize, obtains the Carperitide that meets inner quality standard that purity is greater than 98.5%, total recovery 32.1%.
Embodiment 13: Carperitide Reversed phase high performance liquid chromatography purifying
1. sample preparation: dissolve the inorganic membrane filtration of the solution after dissolving, collection filtrate for later use according to every gram of thick peptide 100 ml pure water ratios.
2. purifying:
Condition: chromatographic column: the chromatographic column that the octadecylsilane chemically bonded silica of take is stationary phase, pillar diameter and length are: 150 mm * 300 mm.Moving phase: A phase: 0.2% acetum is adjusted pH to 2.5～3.5 with ammoniacal liquor; B phase: acetonitrile.Flow velocity: 450-550 ml/min.Detect wavelength: 230 nm.Gradient: B%:17%～32%(60 min).Sample size is 13-15 g.
Operation: rinse chromatographic column well back balance loading with more than 50% acetonitrile, applied sample amount is 13-15g.Linear gradient elution 60min, collects object peak, and the object peptide solution of collection is standby after 28 ℃ of vacuum rotary steams are concentrated into about 10-12 mg/ml.
3, turn salt:
Condition: chromatographic column: the chromatographic column that the octadecylsilane chemically bonded silica of take is stationary phase, pillar diameter and length are: 150 mm * 300 mm.Moving phase: A phase: the aqueous acetic acid of quality solubility 0.1%; B phase: trifluoroacetic acid aqueous solution.Flow velocity: 450-550 ml/min.Detect wavelength: 280 nm.Gradient: B%:6%～36%(60 min).Sample size is 15-20g.
Operation: loading after chromatographic column is clean by more than 50% washed with methanol, applied sample amount is 1500-2000ml sample solution.Linear gradient elution 60min, collects object peak, the object peptide solution of collection is merged to concentrated by rotary evaporation and to about 50-80mg/ml, go to suitable big or small cillin bottle.Lyophilize, obtains the Carperitide that meets inner quality standard that purity is greater than 98.5%, total recovery 30.1%.
Embodiment 14: Carperitide Reversed phase high performance liquid chromatography purifying
1. sample preparation: dissolve the inorganic membrane filtration of the solution after dissolving, collection filtrate for later use according to every gram of thick peptide 100 ml pure water ratios.
2. purifying:
Condition: chromatographic column: the chromatographic column that the octadecylsilane chemically bonded silica of take is stationary phase, pillar diameter and length are: 300mm * 300mm.Moving phase: A phase: 0.2% acetum is adjusted pH to 2.5～3.5 with ammoniacal liquor; B phase: acetonitrile.Flow velocity: 1900-2200 ml/min.Detect wavelength: 230 nm.Gradient: B%:17%～32%(120 min).Sample size is 55-75 g.
Operation: rinse chromatographic column well back balance loading with more than 50% acetonitrile, applied sample amount is 55-75g.Linear gradient elution 120min, collects object peak, and 28 ℃ of vacuum rotary steams of the object peptide solution of collection are concentrated into after about 10-12 mg/ml standby.
3, turn salt:
Condition: chromatographic column: the chromatographic column that the octadecylsilane chemically bonded silica of take is stationary phase, pillar diameter and length are: 300mm * 300mm.Moving phase: A phase: 0.1% aqueous acetic acid; B phase: trifluoroacetic acid aqueous solution.Flow velocity: 1900-2200 ml/min.Detect wavelength: 230 nm.Gradient: B%:6%～36%(90 min).Sample size is 55-75g.
Operation: loading after chromatographic column is clean by more than 50% washed with methanol, applied sample amount is 5500-7500ml sample solution.Linear gradient elution 90min, collects object peak, the object peptide solution of collecting is merged to concentrated by rotary evaporation and to about 50-80mg/ml, go to suitable big or small cillin bottle.Lyophilize, obtains the Carperitide that meets inner quality standard that purity is greater than 98.5%, total recovery 30.3%.
In sum, the present invention adopts the synthetic Carperitide of Fmoc solid phase synthesis strategy, the Reversed phase high performance liquid chromatography purifying without report, have that operation is simple, aftertreatment easily, low, the yield high of raw material less investment, cost, the total recovery of total overall reaction can reach 30%.The present invention has considerable economical and practical value, is with a wide range of applications in the synthetic field of polypeptide drugs design simultaneously.
Claims (4)
1. a preparation method for carperitide acetate, comprises the following steps:
1) the Wang Resin that is 0.5mmol/g-1.0mmol/g by Fmoc-Tyr (tBu)-OH and substitution degree reaction, obtains Fmoc-Tyr (tBu)-Wang Resin;
2) Fmoc-Tyr (tBu)-Wang Resin resin is adopted to synthetic linear Carperitide-Wang Resin, the described step 2 of obtaining of mode of coupling one by one) one by one coupling adopt coupling agent, coupling agent comprises TEA, NMM or DIPEA;
3) adopt the synthetic Carperitide-Wang Resin of iodine phase oxidative, during the synthetic Carperitide-Wang Resin of described employing iodine phase oxidative, the consumption of iodine, in amount, is 10-80 times of Carperitide-Wang Resin amount, and oxidization time is 4-16 hour;
4) adopt TFA cracking, obtain thick peptide;
5) high performance liquid phase purifying Carperitide, comprises the following steps:
The first step purifying: will synthesize the thick peptide dissolving of gained rear is stationary phase with octadecylsilane chemically bonded silica, take phosphate buffer soln as A phase, trifluoroacetic acid aqueous solution are B phase, carries out gradient elution purifying;
Second step turns salt: adopt RP-HPLC method to be changed into acetate.
2. preparation method according to claim 1, is characterized in that: step 5) the first step purifying: take phosphate buffer soln as A phase, buffered soln pH scope is 2.5-3.5; Take trifluoroacetic acid aqueous solution as B phase, and the gradient of B phase is: 17%～32%, carry out gradient elution purifying 45-120min.
3. preparation method according to claim 1, is characterized in that: step 5) second step RP-HPLC method is: using concentration as 0.05--0.1% acetate buffer solution is as A phase; Buffered soln pH is 3.5～4.4; Using trifluoroacetic acid aqueous solution as B phase, and gradient is: 6%～36%, and the gradient elution time is 30-90min, changes into acetate.
4. preparation method according to claim 2, is characterized in that: step 5) second step RP-HPLC method is: using concentration as 0.05--0.1% acetate buffer solution is as A phase; Buffered soln pH is 3.5～4.4; Using trifluoroacetic acid aqueous solution as B phase, and gradient is: 6%～36%, and the gradient elution time is 30-90min, changes into acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110347965.4A CN102382188B (en) | 2011-11-07 | 2011-11-07 | Method for preparing carperitide acetate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110347965.4A CN102382188B (en) | 2011-11-07 | 2011-11-07 | Method for preparing carperitide acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102382188A CN102382188A (en) | 2012-03-21 |
| CN102382188B true CN102382188B (en) | 2014-01-22 |
Family
ID=45822072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110347965.4A Expired - Fee Related CN102382188B (en) | 2011-11-07 | 2011-11-07 | Method for preparing carperitide acetate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102382188B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675450A (en) * | 2012-05-14 | 2012-09-19 | 滨海吉尔多肽有限公司 | Method for purifying thymosin beta4 |
| CN103421081A (en) * | 2012-05-24 | 2013-12-04 | 昆明积大制药股份有限公司 | Method for removing trifluoroacetic acid in polypeptide |
| CN102875664B (en) * | 2012-09-21 | 2014-06-18 | 深圳翰宇药业股份有限公司 | Purifying method of carperitide |
| CN103142489B (en) * | 2012-11-28 | 2014-08-06 | 深圳市健元医药科技有限公司 | Human alpha-atrial natriuretic peptide sustained release microsphere preparation and preparation method thereof |
| CN102993274B (en) * | 2012-11-30 | 2014-08-20 | 深圳翰宇药业股份有限公司 | Purification method of ganirelix acetate |
| CN103880946B (en) * | 2012-12-20 | 2016-06-08 | 深圳翰宇药业股份有限公司 | The preparation method of carperitide |
| CN103204923B (en) * | 2013-03-21 | 2016-06-22 | 深圳翰宇药业股份有限公司 | Solid phase fragment method prepares carperitide |
| CN103342745B (en) * | 2013-05-27 | 2015-06-10 | 成都圣诺生物制药有限公司 | Preparation method of carperitide |
| CN103275189B (en) * | 2013-06-06 | 2014-08-06 | 深圳翰宇药业股份有限公司 | Cracking liquid for peptide resin, and application thereof in synthesizing somatostatin by solid phase cracking |
| CN103396475B (en) * | 2013-08-06 | 2015-08-26 | 深圳翰宇药业股份有限公司 | A kind of method of pure solid-phase synthetic peptide class microbiotic Colistin |
| CN116063451B (en) * | 2022-12-28 | 2023-11-21 | 江苏诺泰澳赛诺生物制药股份有限公司 | Synthetic method of capelin |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101372504B (en) * | 2007-08-22 | 2011-05-18 | 深圳翰宇药业股份有限公司 | Method for purifying desmopressin |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
-
2011
- 2011-11-07 CN CN201110347965.4A patent/CN102382188B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102382188A (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102382188B (en) | Method for preparing carperitide acetate | |
| EP3392266B1 (en) | Linaclotide synthesis method | |
| CN102875655B (en) | Linaclotide synthesis method | |
| CN103864918A (en) | Solid-phase synthesis method for liraglutide | |
| CN107880111B (en) | Method for preparing liraglutide | |
| CN101747426B (en) | Method for synthesizing pramlintide | |
| CN102702320A (en) | Method for preparing eptifibatide | |
| CN104045706A (en) | Synthetic method of liraglutide | |
| CN104861045A (en) | Cyclopeptide compound GG6F and preparation method thereof | |
| CN108148115A (en) | A kind of cyclic peptide new synthetic method and its application in drug development | |
| CN101519444A (en) | Method for preparing Nesiritide | |
| CN106478805A (en) | A kind of preparation method of GLP-1 derivant | |
| CN110204611B (en) | Solid phase fragment method for synthesizing bivalirudin | |
| KR20210102362A (en) | Improved process for making plecanatide | |
| CN111748019A (en) | Synthetic method of polypeptide derivative compound | |
| CN105037496A (en) | Preparation method for eptifibatide | |
| CN110372788B (en) | Synthesis method and application of clarypsin | |
| CN103204923B (en) | Solid phase fragment method prepares carperitide | |
| CN106554407B (en) | Synthetic method of ularitide | |
| CN101712716B (en) | Method for preparing vapreotide | |
| CN102875639A (en) | Solid-phase synthetic method of peptide and peptide synthesized by same | |
| CN103517915B (en) | A kind of method preparing buserelin | |
| CN103880946B (en) | The preparation method of carperitide | |
| CN112010945B (en) | Preparation method of carbetocin impurity Gly9-OH | |
| CN112521482B (en) | Preparation method for synthesizing nesiritide by solid-liquid combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 |